Article Abstract

Revolutionary changes in salvage treatment for Hodgkin lymphoma: toward a chemotherapy-free future

Authors: Jiawen Chen, Wei Yang, Zimu Gong


Recently, O’Connor et al. reported the high activity of the combination of brentuximab vedotin (BV) and bendamustine in relapsed/refractory Hodgkin’s lymphoma (HL) patients (1). The study is notable for the heavily treated population and relatively large sample size.